Ascrinvacumab (ACVRL1/SKR3/TGF-B/ TSR-I) - Research Grade Biosimilar

• Background:

  Ascrinvacumab has been used in trials studying the treatment and basic science of Neoplasms, Advanced Solid Tumors, Carcinoma, Hepatocellular, and Malignant Pleural Mesothelioma.

• Immunogen:

  Homo sapiens / ACVRL1/SKR3/TGF-B/ TSR-I [Homo sapiens]

• Clonality:

  Recombinant Monoclonal

• Conjugation:

  Unconjugated

• Type:

  Primary Antibodies, Biosimilars

• Source:

  CHO cells

• Field of Research:

  Cancer

• Purification:

  >95%

• Concentration:

  Batch dependent

• Buffer:

  PBS buffer pH7.5

• Modification:

  None

• Shipping Conditions:

  Blue Ice

• Storage Conditions:

  Use a manual defrost freezer and avoid repeated freeze thaw cycles. Store at 2 to 8 ˚ C for 1-2 weeks. Store at -20 ˚ C for 12 months. Store at -80 ˚ C for long term storage.

• Fragment:

  IgG2-kappa

• NCBI Organism:

  Homo sapiens

• Other Product Names:

  PF-03446962